|Podcasts|August 26, 2021

Managed Care Cast Presents: MS Stakeholder Summit—New Treatment Landscape in MS, Part 2

In part 2 of this 2-part podcast, a panel of experts discusses newer therapies for multiple sclerosis (MS), switching therapies, and more.

Today, we are bringing you part 2 of a 2-part sponsored podcast series discussing new treatments in multiple sclerosis (MS). In part 1, a panel of experts discussed tailoring treatments to patients with MS, payer considerations, and more.

In this second part of the series, the same panel of experts continues their talk on MS. They will discuss newer therapies, switching therapies, and more.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Managed Care Cast Presents: MS Stakeholder Summit—New Treatment Landscape in MS, Part 2

Related Content

Cancer, Trauma, and Healing the Whole Person

Making Early CKD Detection Count: Ralph Riello, PharmD, and Nihar Desai, MD

Food Insecurity Studies Reveal Key Predictors, Detection Gaps: Jonathan Wrathall, PhD

Psychedelic Therapies Reach Turning Point Amid Federal Push, Says Scott Shannon, MD

Enhanced Cost Messaging Yields Minimal Change in Primary Care Clinic Selection: Tim McDonald, PhD, MPP, and Bryan E. Dowd, PhD

Trending on AJMC

5 FAQs: Ebola Outbreaks and the Challenge of Public Trust

Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox

How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap

Tisagenlecleucel Yields Promising Disease-Free Survival in High-Risk Pediatric ALL: Shannon L. Maude, MD, PhD

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications